Achieve Life Sciences (ACHV) Change in Account Payables (2012 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly Change in Account Payables of -$53000.0 in Q1 2026, up 95.11% on a QoQ basis from -$1.1 million in Q4 2025, and up 81.91% year-over-year from -$29135.1 in Q1 2025.
Achieve Life Sciences (ACHV) Change in Account Payables (2012 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed Change in Account Payables across 15 years of filings, most recently posting -$53000.0 for Q1 2026.
- Quarterly Change in Account Payables rose 81.91% year-over-year to -$53000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$851000.0 (down 166.28% YoY) and the FY2025 annual result came in at -$1.1 million, down 181.91% from the prior year.
- Change in Account Payables rose to -$53000.0 in Q1 2026, from -$1.1 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.2 million in Q4 2022 and troughed at -$1.1 million in Q4 2025.
- A 5-year average of -$3235.3 and a median of -$53000.0 in 2026 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2023 — Change in Account Payables slumped 394.96% — and 2024, when it surged 4795.0%.
- Tracing ACHV's Change in Account Payables over 5 years: stood at $1.2 million in 2022, then sank by 101.63% to -$20000.0 in 2023, then jumped by 4795.0% to $939000.0 in 2024, then slumped by 215.44% to -$1.1 million in 2025, then surged by 95.11% to -$53000.0 in 2026.
- Business Quant data shows ACHV's Change in Account Payables at -$53000.0 in Q1 2026, -$1.1 million in Q4 2025, and $725000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -53,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53,000.00 |
| Mar 31, 2026 | -53,000.00 |
| Dec 31, 2025 | -1.08 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | 725,000.00 |
| Sep 30, 2025 | 725,000.00 |
| Jun 30, 2025 | -439,000.00 |
| Jun 30, 2025 | -439,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Mar 31, 2025 | -293,000.00 |
| Dec 31, 2024 | 939,000.00 |
| Dec 31, 2024 | 939,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Jun 30, 2024 | 177,000.00 |
| Mar 31, 2024 | -245,000.00 |
| Mar 31, 2024 | -245,000.00 |
| Dec 31, 2023 | -20,000.00 |
| Dec 31, 2023 | -20,000.00 |